Variable | Early therapy n = 88 | Delayed therapy n = 62 | P value |
---|---|---|---|
Age, years | |||
Mean ± SD | 34.86 ± 8.1 | 34.82 ± 7.6 | 0.97 |
Gender, number (%): | |||
Male | 74 (84.1%) | 52 (83.9%) | |
Female | 14 (15.9%) | 10 (16.1%) | 0.971 |
BMI, kg/m2: | |||
Mean ± SD | 17.9 ± 2.8 | 18.4 ± 2.1 | |
Hemoglobin, mg/dl | |||
Mean ± SD | 10.6 ± 1.7 | 11.0 ± 1.9 | |
CD4 count, cells/mm3: | |||
Median | 133 | 152 | |
(Range) | (7 – 588) | ( 14 – 648 ) | |
log10viral load/ml: | |||
Median | 5.36 | 5.30 | |
(Range) | (2.42–5.88) | (2.33–5.88) | |
Non TB OI’s : | |||
number (%) | 12 (13.6%) | 10 (16.1%) | 0.671 |
WHO Staging of HIV disease, number (%): | |||
Stage 3 | 19(21.6%) | 15 (24.2%) | 0.70 |
Stage 4 | 69 (78.4%) | 47 (75.8%) | (overall) |
Type of Tuberculosis, number (%): | |||
PTB | 19 (21.6%) | 15 (24.2%) | |
PTB with Dissemination | 33 (37.5%) | 26 (41.9%) | 0.367 |
EPTB | 18 (20.4%) | 15 (24.2%) | (overall) |
EPTB with Dissemination | 18 (20.4%) | 06 (09.7%) | |
DOTS Category of ATT, number (%): | |||
Category I (2H3R3Z3E3 + 4H3R3) | 83 (94.3%) | 61 (98.4%) | 0.214 |
Category II (2H3R3Z3E3S3 + 1H3R3Z3E3 + 5H3R3E3) | 05 (5.7%) | 01 (1.6%) | (overall) |